Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Keystone State Herald.
Press releases published on June 18, 2025
The Goddard School Announces 2025 Circle of Excellence and President’s Club Members
GlobeNewswire
·
June 18, 2025
King of Prussia, PA, June 18, 2025 (GLOBE NEWSWIRE) -- The Goddard School®, the nation’s leading premium early childhood education provider, today announced its 2025 Circle of Excellence and 2025 President’s Club members. These honors recognize the very …
Omega Flex, Inc. Announces Regular Quarterly Dividend for the Second Quarter 2025
GlobeNewswire
·
June 18, 2025
EXTON, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Omega Flex, Inc. (the “Company”) (NASDAQ: OFLX) today announced that the Board of Directors declared a regular quarterly dividend of $0.34 per share payable on July 10, 2025, to shareholders of record on June …
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
GlobeNewswire
·
June 18, 2025
Presentation underscores unique potential for atrioventricular interval modulation (“AVIM”) therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with preserved ejection …
ACNB Corporation Announces Common Stock Repurchase Program
GlobeNewswire
·
June 18, 2025
GETTYSBURG, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- ACNB Corporation (“ACNB”) (NASDAQ: ACNB), financial holding company for ACNB Bank and ACNB Insurance Services, Inc., announced today that the Board of Directors approved a new plan to repurchase, in open …
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
GlobeNewswire
·
June 18, 2025
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage …